Significance of effector protease receptor-1 expression and its relationship with proliferation and apoptotic index in patients with primary advanced gastric adenocarcinoma

World Journal of Gastroenterology

Volumn 10, Issue 9, 2004, Pages 1262-1267

  Yao, Xue Quan ^a   Liu, Fu Kun ^a   Li, Jie Shou ^a   Qi, Xiao Ping ^a   Wu, Bo ^a   Yin, Hong Lin ^a   Ma, Heng Hui ^a   Shi, Qun Li ^a   Zhou, Xiao Jun ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EFFECTOR PROTEASE RECEPTOR 1; KI 67 ANTIGEN; PARAFFIN; RECEPTOR; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; APOPTOSIS; ARTICLE; CANCER CLASSIFICATION; CANCER INVASION; CARCINOMA CELL; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CLINICAL PRACTICE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOPLASM; FEMALE; FREQUENCY ANALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LABELING INDEX; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; NICK END LABELING; PROTEIN EXPRESSION; SCORING SYSTEM; SMOOTH MUSCLE FIBER; STATISTICAL SIGNIFICANCE; STOMACH ADENOCARCINOMA; STOMACH MUCOSA; TUMOR DIFFERENTIATION;

EID: 4444241490     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v10.i9.1262     Document Type: Article

References (32)

1. Lu CD, Altieri DC, Tanigawa N. Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. Cancer Res 1998; 58: 1808-1812
2. Altieri DC. Molecular cloning of effector cell protease receptor-1, a novel cell surface receptor for the protease factor Xa. J Biol Chem 1994; 269: 3139-3142
3. Bouchard BA, Silveira JR, Tracy PB. On the role of EPR-1 or an EPR-1-like molecule in regulating factor Xa incorporation into platelet prothrombinase. Thromb Haemost 2001; 86: 1133-1135
4. McLean K, Schirm S. Johns A, Morser J, Light DR. FXa-induced responses in vascular wall cells are PAR-mediated and inhibited by ZK-807834. Thromb Res 2001; 103: 281-297
5. Blanc-Brude OP, Chambers RC, Leoni P, Dik WA, Laurent GJ. Factor Xa is a fibroblast mitogen via binding to effector-cell protease receptor-1 and autocrine release of PDGF. Am J Physiol Cell Physiol 2001; 281: C681-689
6. Cirera S, Fredholm M. Isolation and mapping the pig homologs survivin (BIRC5) and effector cell protease receptor 1 (EPR1) genes. Cytogenet Cell Genet 2001; 92: 351-352
7. Kawabata A, Kuroda R, Nakaya Y, Kawai K, Nishikawa H, Kawao N. Factor Xa-evoked relaxation in rat aorta: involvement of PAR-2. Biochem Biophys Res Commun 2001; 282: 432-435
8. Monno R, Grandaliano G, Faccio R, Ranieri E, Martino C, Gesualdo L, Schena FP. Activated coagulation factor X: a novel mitogenic stimulus for human mesangial cells. J Am Soc Nephrol 2001; 12: 891-899
9. Shinozawa I, Inokuchi K, Wakabayashi I, Dan K. Disturbed expression of the anti-apoptosis gene, survivin, and EPR-1 in hematological malignancies. Leuk Res 2000; 24: 965-970
10. Altieri DC. Splicing of effector cell protease receptor-1 mRNA is modulated by an unusual retained intron. Biochemistry 1994; 33: 13848-13855
11. Altieri DC. Molecular cloning of effector cell protease receptor-1, a novel cell surface receptor for the protease factor Xa. J Biol Chem 1994; 269: 3139-3142
12. Ambrosini G, Adida C, Sirugo G, Altieri DC. Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting. J Biol Chem 1998; 273: 11177-11182
13. Zaffaroni N, Daidone MG. Survivin expression and resistance to anticancer treatments: perspectives for new therapeutic interventions. Drug Resist Updat 2002; 5: 65-72
14. Takai N, Miyazaki T, Nishida M, Nasu K, Miyakawa I. Survivin expression correlates with clinical stage, histological grade, invasive behavior and survival rate in endometrial carcinoma. Cancer Lett 2002; 184: 105-116
15. Fortugno P, Wall NR, Giodini A, O'Connor DS, Plescia J, Padgett KM, Tognin S, Marchisio PC, Altieri DC. Survivin exists in immunochemically distinct subcellular pools and is involved in spindle microtubule function. J Cell Sci 2002; 115 (Pt 3): 575-585
16. Kanwar JR, Shen WP, Kanwar RK, Berg RW, Krissansen GW. Effects of survivin antagonists on growth of established tumors and B7-1 immunogene therapy. J Natl Cancer Inst 2001; 93: 1541-1552
17. Adida C, Crotty PL, McGrath J, Berrebi D, Diebold J, Altieri DC. Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation. Am J Pathol 1998; 152: 43-49
18. Shinozawa I, Inokuchi K, Wakabayashi I, Dan K. Disturbed expression of the anti-apoptosis gene, survivin, and EPR-1 in hematological malignancies. Leuk Res 2000; 24: 965-970
19. Yamamoto T, Manome Y, Nakamura M, Tanigawa N. Downregulation of survivin expression by induction of the effector cell protease receptor-1 reduces tumor growth potential and results in an increased sensitivity to anticancer agents in human colon cancer. Eur J Cancer 2002; 38: 2316-2324
20. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol 2000; 182: 311-322
21. Aoki T, Inoue S, Imamura H, Fukushima J, Takahashi S, Urano T, Hasegawa K, Ogushi T, Ouchi Y, Makuuchi M. EBAG9/ RCAS1 expression in hepatocellular carcinoma: correlation with tumour dedifferentiation and proliferation. Eur J Cancer 2003; 39: 1552-1561
22. Nieto A, Perez-Alenza MD, Del Castillo N, Tabanera E, Castano M, Pena L. BRCA1 expression in canine mammary dysplasias and tumours: relationship with prognostic variables. J Comp Pathol 2003; 128: 260-268
23. Friedrich RE, Hagel C, Brehme Z, Kluwe L, Mautner VF. Ki-67 proliferation-index (MIB-1) of neurofibromas in neurofibromatosis type 1 patients. Anticancer Res 2003; 23: 953-955
24. Sredni ST, Alves VA, Latorre Mdo R, Zerbini MC. Adrenocortical tumours in children and adults: a study of pathological and proliferation features. Pathology 2003; 35: 130-135
25. Grabsch H, Takeno S, Parsons WJ, Pomjanski N, Boecking A, Gabbert HE, Mueller W. Overexpression of the mitotic checkpoint genes BUB1, BUBR1, and BUB3 in gastric cancer association with tumour cell proliferation. J Pathol 2003; 200: 16-22
26. Furuya Y, Kawauchi Y, Fuse H. Cell proliferation, apoptosis and prognosis in patients with metastatic prostate cancer. Anticancer Res 2003; 23: 577-581
27. Watanabe J, Sato H, Kanai T, Kamata Y, Jobo T, Hata H, Fujisawa T, Ohno E, Kameya T, Kuramoto H. Paradoxical expression of cell cycle inhibitor p27 in endometrioid adenocarcinoma of the uterine corpus - correlation with proliferation and clinicopathological parameters. Br J Cancer 2002; 87: 81-85
28. Rudolph P, Bonichon F, Gloeckner K, Collin F, Chassevent A, Schmidt D, Coindre JM, Parwaresch R, Kloppel G. Comparative analysis of prognostic indicators for sarcomas of the soft parts and the viscerae. Verh Dtsch Ges Pathol 1998; 82: 246-252
29. Janicke F. Value of tumor biological prognostic factors in adjuvant therapy of node-negative breast cancer. Zentralbl Gynakol 1994; 116: 449-455
30. Kase S, Osaki M, Honjo S, Adachi H, Ito H. Tubular adenoma and intramucosal intestinal-type adenocarcinoma of the stomach: what are the pathobiological differences? Gastric Cancer 2003; 6: 71-79
31. Uysal H, Cevik IU, Soylemezoglu F, Elibol B, Ozdemir YG, Evrenkaya T, Saygi S, Dalkara T. Is the cell death in mesial temporal sclerosis apoptotic? Epilepsia 2003; 44: 778-784
32. Bendardaf R, Ristamaki R, Kujari H, Laine J, Lamlum H, Collan Y, Pyrhonen S. Apoptotic index and bcl-2 expression as prognostic factors in colorectal carcinoma. Oncology 2003; 64: 435-442